Atossa Therapeutics, Inc.

BST:YAG2 株式レポート

時価総額:€165.4m

Atossa Therapeutics 過去の業績

過去 基準チェック /06

Atossa Therapeutics's earnings have been declining at an average annual rate of -13.7%, while the Biotechs industry saw earnings growing at 13.4% annually.

主要情報

-13.7%

収益成長率

56.1%

EPS成長率

Biotechs 業界の成長-14.6%
収益成長率n/a
株主資本利益率-32.3%
ネット・マージンn/a
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

収支内訳

Atossa Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

BST:YAG2 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 240-261317
31 Mar 240-301418
31 Dec 230-301417
30 Sep 230-301417
30 Jun 230-321417
31 Mar 230-281317
31 Dec 220-271315
30 Sep 220-241212
30 Jun 220-21129
31 Mar 220-22129
31 Dec 210-21119
30 Sep 210-281010
30 Jun 210-2699
31 Mar 210-2387
31 Dec 200-2287
30 Sep 200-1385
30 Jun 200-1385
31 Mar 200-16106
31 Dec 190-17117
30 Sep 190-17107
30 Jun 190-17106
31 Mar 190-2585
31 Dec 180-2374
30 Sep 180-2374
30 Jun 180-2273
31 Mar 180-1152
31 Dec 170-1152
30 Sep 170-1152
30 Jun 170-952
31 Mar 170-651
31 Dec 160-661
30 Sep 160-671
30 Jun 160-1092
31 Mar 160-12102
31 Dec 150-13102
30 Sep 150-13101
30 Jun 150-13101
31 Mar 150-1391
31 Dec 140-1291
30 Sep 140-1292
30 Jun 140-12101
31 Mar 140-11101
31 Dec 131-11101

質の高い収益: YAG2 is currently unprofitable.

利益率の向上: YAG2 is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: YAG2 is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.

成長の加速: Unable to compare YAG2's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: YAG2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16%).


株主資本利益率

高いROE: YAG2 has a negative Return on Equity (-32.32%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘